---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009380"
form_type: "8-K"
ticker: null
cik: "0001460602"
company_name: "Orgenesis Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T05:49:07.694174+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Orgenesis acquires spinal cord injury IP assets from Neurocords for 1.2M shares

## Summary
- Acquired IP assets for advanced regenerative therapies for spinal cord injuries from Neurocords, LLC.
- Issued 1,200,000 shares of common stock as consideration; shares restricted for 6 months then free-trading.
- Transaction closed March 3, 2025; prior licensing agreements terminated and mutual releases executed.
- Orgenesis also gets a 3-month option to acquire Rice University option agreement at no additional cost.

## SEC filing metadata
- accession: 0001493152-25-009380
- form_type: 8-K
- cik: 0001460602
- company_name: Orgenesis Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460602/000149315225009380/0001493152-25-009380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460602/000149315225009380/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009380
- JSON: https://secwatch.observer/filing/0001493152-25-009380.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009380.txt

## Key facts
- M&A Transactions
  Orgenesis Inc. completed an acquisition involving Neurocords, LLC. for 1,200,000 (one million and two hundred thousand) shares of common stock of Orgenesis.
  - Action: acquisition
  - Counterparty: Neurocords, LLC.
  - Consideration: 1,200,000 (one million and two hundred thousand) shares of common stock of Orgenesis
  source text: Asset Purchase Agreement, in consideration for the purchase of the Assets, the Company will issue to Neurocords or any other person or entity designated in writing by Neurocords 1,200,000 (one million and two hundred thousand) shares of common stock of Orgenesis, free and clear of any trading restrictions after the initial 6-month restricted period, or any other
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460602/000149315225009380/0001493152-25-009380-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.